← Back to Search

Exparel for Post-Surgery Pain Management in Thyroid Conditions

Q: Are there any open slots in this research program for volunteers?

Unfortunately, this research is no longer taking on any additional participants. It was initially posted on September 30th 2019 and the last update occurred April 12th 2021. If you are still searching for clinical trials to join, there are 87 studies recruiting individuals with <a href="https://www.withpower.com/clinical-trials/thyroid">thyroid</a> issues and 231 being conducted using a combination of Lidocaine Epinephrine and Bupivacaine Hydrochloride-EPINEPHrine as interventions.

Q: Has research previously been conducted on the combination of Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine?

Currently, 231 medical trials are investigating the effects of Lidocaine Epinephrine and Bupivacaine Hydrochloride-EPINEPHrine. Out of those 231 studies, 53 have reached Phase 3. Despite its base in Germantown, <a href="https://www.withpower.com/clinical-trials/tennessee">Tennessee</a>; this treatment is being studied across 1,265 different locations worldwide.

Q: For what medical conditions is the Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine combination employed?

Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine is prescribed for the treatment of ophthalmia and sympathetic issues. It has also proven to be efficacious in alleviating laryngotracheobronchitis, permphigus and unresponsive bradycardia symptoms.

Q: What is the current number of participants in this research trial?

This research initiative is no longer enrolling patients. Initially listed on September 30th 2019 and last modified April 12 2021, the trial has since concluded its recruitment phase. For those seeking alternative studies, 87 trials are presently recruiting for <a href="https://www.withpower.com/clinical-trials/thyroid">Thyroid</a> related issues while 231 seek participants with Lidocaine Epinephrine or Bupivacaine Hydrochloride-EPINEPHrine conditions.

Phase < 1

Waitlist Available

Led By Tabitha Galloway, MD

Research Sponsored by University of Missouri-Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients requiring parathyroid/thyroid surgery based on the standard of care

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up after surgery, patients will be monitored for two weeks, until they return for their first postoperative appointment.

Awards & highlights

Study Summary

This trial is testing whether a medication called Exparel can decrease the amount of opioids needed for pain control after surgery.

Who is the study for?

This trial is for English-speaking adults over 18 who need thyroid or parathyroid surgery. It's not open to those under 18, with a history of opioid abuse, or allergies to local anesthetics or opioids.Check my eligibility

What is being tested?

The study tests if Exparel, when injected during surgery, reduces the need for opioid painkillers after thyroid and parathyroid surgeries. It aims to improve postoperative pain management.See study design

What are the potential side effects?

Possible side effects may include reactions at the injection site such as swelling and redness, nerve damage symptoms like numbness or tingling, allergic reactions, and low blood pressure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I need surgery for my parathyroid or thyroid as recommended by my doctor.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ after surgery, patients will be monitored for two weeks, until they return for their first postoperative appointment.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~after surgery, patients will be monitored for two weeks, until they return for their first postoperative appointment.

This trial's timeline: 3 weeks for screening, Varies for treatment, and after surgery, patients will be monitored for two weeks, until they return for their first postoperative appointment. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of opioid use when given Exparel intraoperatively

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Exparel InjectionExperimental Treatment1 Intervention

Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision

Group II: Bupivicaine HCLExperimental Treatment1 Intervention

Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.

Group III: Current PracticeActive Control1 Intervention

Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor

361 Previous Clinical Trials

627,894 Total Patients Enrolled

Tabitha Galloway, MDPrincipal InvestigatorUniversity of Missouri Department of Otolaryngology-Head and Neck Surgery

Media Library

Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine Clinical Trial Eligibility Overview. Trial Name: NCT04085913 — Phase < 1

Parathyroid Adenomas Research Study Groups: Exparel Injection, Bupivicaine HCL, Current Practice

Parathyroid Adenomas Clinical Trial 2023: Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine Highlights & Side Effects. Trial Name: NCT04085913 — Phase < 1

Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine 2023 Treatment Timeline for Medical Study. Trial Name: NCT04085913 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots in this research program for volunteers?

"Unfortunately, this research is no longer taking on any additional participants. It was initially posted on September 30th 2019 and the last update occurred April 12th 2021. If you are still searching for clinical trials to join, there are 87 studies recruiting individuals with thyroid issues and 231 being conducted using a combination of Lidocaine Epinephrine and Bupivacaine Hydrochloride-EPINEPHrine as interventions."

Answered by AI

Has research previously been conducted on the combination of Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine?

"Currently, 231 medical trials are investigating the effects of Lidocaine Epinephrine and Bupivacaine Hydrochloride-EPINEPHrine. Out of those 231 studies, 53 have reached Phase 3. Despite its base in Germantown, Tennessee; this treatment is being studied across 1,265 different locations worldwide."

Answered by AI

For what medical conditions is the Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine combination employed?

"Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine is prescribed for the treatment of ophthalmia and sympathetic issues. It has also proven to be efficacious in alleviating laryngotracheobronchitis, permphigus and unresponsive bradycardia symptoms."

Answered by AI

What is the current number of participants in this research trial?

"This research initiative is no longer enrolling patients. Initially listed on September 30th 2019 and last modified April 12 2021, the trial has since concluded its recruitment phase. For those seeking alternative studies, 87 trials are presently recruiting for Thyroid related issues while 231 seek participants with Lidocaine Epinephrine or Bupivacaine Hydrochloride-EPINEPHrine conditions."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Exparel Injection Effect on Postoperative Opioid Usage

Tabitha L. Galloway 2019. "Exparel Injection Effect on Postoperative Opioid Usage". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04085913.

All > Lidocaine > Exparel